Vera Therapeutics, Inc. (VERA)
NASDAQ: VERA · IEX Real-Time Price · USD
39.48
-0.53 (-1.32%)
Apr 18, 2024, 4:00 PM EDT - Market closed
Company Description
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases.
Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.
It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections.
The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020.
Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.
Vera Therapeutics, Inc.
| Country | United States |
| Founded | 2016 |
| IPO Date | May 14, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 51 |
| CEO | Dr. Marshall W. Fordyce M.D. |
Contact Details
Address: 8000 Marina Boulevard, Suite 120 Brisbane, California 94005 United States | |
| Phone | 650-770-0077 |
| Website | veratx.com |
Stock Details
| Ticker Symbol | VERA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $11.00 |
| CIK Code | 0001831828 |
| CUSIP Number | 92337R101 |
| ISIN Number | US92337R1014 |
| Employer ID | 81-2744449 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Marshall W. Fordyce M.D. | Founder, President, Chief Executive Officer and Director |
| Sean P. Grant M.B.A. | Chief Financial Officer |
| Joseph R. Young M.B.A. | Senior Vice President of Finance and Chief Accounting Officer |
| Julien E. Capers J.D. | Vice President and Head of Legal |
| Kelly Rauber | Vice President and Head of Human Resources |
| Tom Doan | Senior Vice President of Development Operations |
| Lauren Frenz | Chief Business Officer |
| Dr. Neeraj Pakala M.B.A., Ph.D. | Senior Vice President and Head of Product Development and Manufacturing |
| Dr. Kerry Cooper M.D. | Senior Vice President of Medical Affairs |
| Dr. Robert M. Brenner M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 4, 2024 | ARS | Filing |
| Apr 3, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 3, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 3, 2024 | 144 | Filing |
| Mar 27, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 27, 2024 | 10-K | Annual Report |
| Mar 26, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Mar 21, 2024 | 144 | Filing |
| Mar 20, 2024 | 8-K | Current Report |
| Feb 20, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |